Illumina (NASDAQ:ILMN) Reaches New 1-Year Low – What’s Next?

Shares of Illumina, Inc. (NASDAQ:ILMN) reached a new 52-week low during trading on Tuesday . The company traded as low as $99.33 and last traded at $100.01, with a volume of 1715757 shares. The stock had previously closed at $100.24.

Analyst Ratings Changes

A number of research firms have commented on ILMN. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and cut their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and cut their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, Robert W. Baird boosted their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Stock Performance

The firm has a market cap of $15.40 billion, a P/E ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business’s fifty day simple moving average is $128.97 and its 200-day simple moving average is $134.16.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently modified their holdings of ILMN. Capital World Investors lifted its position in shares of Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock worth $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Brown Advisory Inc. lifted its position in shares of Illumina by 54,220.9% in the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock worth $255,586,000 after purchasing an additional 1,909,118 shares during the period. Norges Bank purchased a new stake in shares of Illumina in the 4th quarter worth about $228,714,000. Bessemer Group Inc. lifted its position in shares of Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock worth $180,152,000 after purchasing an additional 1,344,038 shares during the period. Finally, WCM Investment Management LLC lifted its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.